These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1732635)
21. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Shimizu Y; Weidmann E; Iwatsuki S; Herberman RB; Whiteside TL Cancer Res; 1991 Nov; 51(22):6153-62. PubMed ID: 1718596 [TBL] [Abstract][Full Text] [Related]
22. Correlation between class I antigen expression and the ability to generate tumour infiltrating lymphocytes from bladder tumour biopsies. Nouri AM; dos Santos AV; Crosby D; Oliver RT Br J Cancer; 1991 Dec; 64(6):996-1000. PubMed ID: 1764393 [TBL] [Abstract][Full Text] [Related]
23. Anti-tumor effect of tumor necrosis factor and its induction of tumor variant of MBT-2 transitional cell carcinoma of the bladder. Kadhim SA; Chin JL J Urol; 1988 May; 139(5):1091-4. PubMed ID: 3361654 [TBL] [Abstract][Full Text] [Related]
24. [Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells, and effect of interferon-alpha and/or cimetidine on the expression]. Wu XX; Mizutani Y; Kakehi Y; Nakamura E; Mitsumori K; Takahashi T; Terachi T; Okada Y; Yoshida O Hinyokika Kiyo; 1998 Sep; 44(9):621-6. PubMed ID: 9805665 [TBL] [Abstract][Full Text] [Related]
25. Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide. Borden EC; Sidky YA; Groveman DS; Bryan GT Cancer Res; 1985 Jan; 45(1):45-50. PubMed ID: 3965150 [TBL] [Abstract][Full Text] [Related]
26. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077 [TBL] [Abstract][Full Text] [Related]
27. Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. Weber JS; Rosenberg SA J Natl Cancer Inst; 1990 May; 82(9):755-61. PubMed ID: 2109092 [TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966 [TBL] [Abstract][Full Text] [Related]
29. Enhanced cell-mediated cytotoxicity by interferon-gamma and interleukin-2 against syngeneic murine mammary adenocarcinoma. Nakajima I; Chu TM Mol Biother; 1992 Mar; 4(1):47-52. PubMed ID: 1627274 [TBL] [Abstract][Full Text] [Related]
30. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells. Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146 [TBL] [Abstract][Full Text] [Related]
31. Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy. Kadhim SA; Chin JL Urol Res; 1991; 19(1):57-62. PubMed ID: 1674182 [TBL] [Abstract][Full Text] [Related]
33. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. Connor J; Bannerji R; Saito S; Heston W; Fair W; Gilboa E J Exp Med; 1993 Apr; 177(4):1127-34. PubMed ID: 8459207 [TBL] [Abstract][Full Text] [Related]
34. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928 [TBL] [Abstract][Full Text] [Related]
35. Interleukin 2 suppression of a murine bladder cancer implanted into kidney, bladder and skin; its organ specificity. Lee KE; O'Donnell RW; Weiss GH; Cockett AT J Urol; 1988 Oct; 140(4):840-3. PubMed ID: 3262172 [TBL] [Abstract][Full Text] [Related]
36. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. Jackson AM; Hawkyard SJ; Prescott S; Ritchie AW; James K; Chisholm GD J Urol; 1992 Jan; 147(1):207-11. PubMed ID: 1729534 [TBL] [Abstract][Full Text] [Related]
37. A correlation between the expression of CD 8 antigen and specific cytotoxicity of tumor-infiltrating lymphocytes. Okada Y; Yahata G; Takeuchi S; Seidoh T; Tanaka K Jpn J Cancer Res; 1989 Mar; 80(3):249-56. PubMed ID: 2524461 [TBL] [Abstract][Full Text] [Related]
38. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status. Ritter M; Huber C; Auböck J; Pohl-Markl H; Troppmair J; Herold M; Gächter A; Nussbaumer W; Böck G; Nachbaur D Immunology; 1994 Apr; 81(4):569-77. PubMed ID: 7913694 [TBL] [Abstract][Full Text] [Related]